Matt Cravets

958 total citations
17 papers, 679 citations indexed

About

Matt Cravets is a scholar working on Surgery, Pathology and Forensic Medicine and Rheumatology. According to data from OpenAlex, Matt Cravets has authored 17 papers receiving a total of 679 indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Surgery, 5 papers in Pathology and Forensic Medicine and 5 papers in Rheumatology. Recurrent topics in Matt Cravets's work include Inflammatory Bowel Disease (4 papers), Helicobacter pylori-related gastroenterology studies (3 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Matt Cravets is often cited by papers focused on Inflammatory Bowel Disease (4 papers), Helicobacter pylori-related gastroenterology studies (3 papers) and Autoimmune and Inflammatory Disorders Research (3 papers). Matt Cravets collaborates with scholars based in United States, Canada and Netherlands. Matt Cravets's co-authors include Edward Keystone, David Hagerty, Gerd R Burmester, Charles Peterfy, Mark C. Genovese, Stanley Cohen, Paul Frohna, Allan Olson, Sheila Gujrathi and Paul P. Tak and has published in prestigious journals such as Blood, Gastroenterology and The Lancet Neurology.

In The Last Decade

Matt Cravets

17 papers receiving 659 citations

Peers

Countries citing papers authored by Matt Cravets

Since Specialization

Citations

This map shows the geographic impact of Matt Cravets's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Matt Cravets with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Matt Cravets more than expected).

Fields of papers citing papers by Matt Cravets

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Matt Cravets. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Matt Cravets. The network helps show where Matt Cravets may publish in the future.

Co-authorship network of co-authors of Matt Cravets

This figure shows the co-authorship network connecting the top 25 collaborators of Matt Cravets. A scholar is included among the top collaborators of Matt Cravets based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Matt Cravets. Matt Cravets is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

17 of 17 papers shown

#	Work	Indexed citations
1	Trial in Progress: A Phase 1b/2 Study of GB5121, a Brain-Penetrant, Potent, Highly Selective, and Irreversible BTK Inhibitor for Relapsed/Refractory Primary/Secondary CNS Lymphoma and Primary Vitreoretinal Lymphoma 2022 ·Blood ·Carole Soussain, Samar Issa, Katharine L. Lewis, (unknown), (unknown), (unknown), (unknown), Matt Cravets, (unknown), (unknown), Brian J. Kirby, (unknown), (unknown), Mark J. Rose, (unknown), Han W. Tun	1
2	A Phase 1b, Multi-Center, Randomized, Placebo-Controlled Trial of Inhaled Seralutinib in Subjects with WHO Group 1 Pulmonary Arterial Hypertension 2021 ·Robert P. Frantz, (unknown), J.W. McConnell, (unknown), R.F. Roscigno, Matt Cravets, Robert J. McCaffrey, Lawrence S. Zisman, Luke Howard	2
3	TORREY, a Phase 2 study to evaluate the efficacy and safety of inhaled seralutinib for the treatment of pulmonary arterial hypertension 2021 ·Pulmonary Circulation ·Robert P. Frantz, Raymond L. Benza, Richard N. Channick, Kelly Chin, Luke Howard, Vallerie V. McLaughlin, Olivier Sitbon, Roham T. Zamanian, Anna R. Hemnes, Matt Cravets, Jean‐Marie Bruey, R.F. Roscigno, David Mottola, (unknown), Lawrence S. Zisman, Hossein Ardeschir Ghofrani	37
4	Phase 1A Randomized Double-Blind Placebo-Controlled Single-Ascending Dose and Multiple- Ascending Dose Studies of Orally Inhaled GB002 in Healthy Adult Subjects 2020 ·(unknown), Mason Yamashita, Matt Cravets, Cynthia Zamora, Robert J. McCaffrey, R. Aranda, Lawrence S. Zisman	3
5	Bioequivalence of HTX-019 (aprepitant IV) and fosaprepitant in healthy subjects: a Phase I, open-label, randomized, two-way crossover evaluation 2018 ·Drug Design Development and Therapy ·(unknown), (unknown), Matt Cravets, Neil J. Clendeninn, Barry Quart	22
6	Safety of HTX-019 (intravenous aprepitant) and fosaprepitant in healthy subjects 2018 ·Future Oncology ·(unknown), (unknown), (unknown), Matt Cravets, Kimberly J. Manhard, Neil J. Clendeninn, Barry Quart	19
7	HTX-019 via 2-Min Injection or 30-Min Infusion in Healthy Subjects 2018 ·Future Oncology ·(unknown), (unknown), (unknown), Matt Cravets, Kimberly J. Manhard, Neil J. Clendeninn, Barry Quart	10
8	Safety and efficacy of the selective sphingosine 1-phosphate receptor modulator ozanimod in relapsing multiple sclerosis (RADIANCE): a randomised, placebo-controlled, phase 2 trial 2016 ·The Lancet Neurology ·Jeffrey A. Cohen, Douglas L. Arnold, Cristoforo Comi, Amit Bar‐Or, Sheila Gujrathi, Jeffrey Hartung, Matt Cravets, Allan Olson, Paul Frohna, Krzysztof Selmaj	144
9	857 Ozanimod Induces Histological Response and Remission: Results From the TOUCHSTONE Study, a Randomized, Double-Blind, Placebo-Controlled Trial of Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis 2016 ·Gastroenterology ·William J. Sandborn, Brian G. Feagan, Geert D’Haens, Barrett G. Levesque, Rish K. Pai, Stephen B. Hanauer, Douglas C. Wolf, Séverine Vermeire, Subrata Ghosh, Heather Smith, Matt Cravets, Paul Frohna, Sheila Gujrathi, Richard Aranda, Allan Olson	3
10	Safety and Efficacy of Long-Term Treatment with Ozanimod, an Oral S1P Receptor Modulator, in Moderate to Severe Ulcerative Colitis: Touchstone Extension 2016 ·The American Journal of Gastroenterology ·William J. Sandborn, Brian Feagan, Geert D’Haens, Stephen B. Hanauer, Douglas C. Wolf, Séverine Vermeire, Subrata Ghosh, Heather Smith, Matt Cravets, Paul Frohna, Richard Aranda, Allan Olson	3
11	An open-label, 6-month study of allopurinol safety in gout: The LASSO study 2015 ·Seminars in Arthritis and Rheumatism ·Michael A. Becker, David Fitzpatrick, Hyon K. Choi, Nicola Dalbeth, Chris Storgard, Matt Cravets, Scott Baumgartner	90
12	445 The TOUCHSTONE Study: A Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis 2015 ·Gastroenterology ·William J. Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert D’Haens, Séverine Vermeire, Stephen B. Hanauer, Subrata Ghosh, Heather Smith, Matt Cravets, Paul Frohna, Sheila Gujrathi, Allan Olson	11
13	445 The TOUCHSTONE Study: a Randomized, Double-Blind, Placebo-Controlled Induction Trial of an Oral S1P Receptor Modulator (RPC1063) in Moderate to Severe Ulcerative Colitis 2015 ·Gastrointestinal Endoscopy ·William J. Sandborn, Brian G. Feagan, Douglas C. Wolf, Geert D’Haens, Séverine Vermeire, Stephen B. Hanauer, Subrata Ghosh, Heather Smith, Matt Cravets, Paul Frohna, Sheila Gujrathi, Allan Olson	1
14	FRI0370 Efficacy and safety of lesinurad (RDEA594), a novel URAT1 inhibitor, in combination with allopurinol in allopurinol-refractory gout patients: Results from a randomized, blinded, placebo-controlled, phase 2b extension study 2012 ·Annals of the Rheumatic Diseases ·Fernando Pérez-Ruiz, John S. Sundy, Eswar Krishnan, V. Hingorani, (unknown), (unknown), Kimberly J. Manhard, Matt Cravets, David Hagerty, Barry Quart	12
15	Continued inhibition of structural damage over 2 years in patients with rheumatoid arthritis treated with rituximab in combination with methotrexate 2010 ·Annals of the Rheumatic Diseases ·Stanley Cohen, Edward Keystone, Mark C. Genovese, (unknown), Charles Peterfy, Paul P. Tak, Matt Cravets, Tim Shaw, David Hagerty	62
16	Improvement in patient‐reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti–tumor necrosis factor therapy 2008 ·Arthritis Care & Research ·Edward Keystone, Gerd R Burmester, R. Furie, (unknown), Paul Emery, Joel M. Kremer, Paul P. Tak, Michael S. Broder, Elaine Yu, Matt Cravets, (unknown), F Jost	86
17	Rituximab inhibits structural joint damage in patients with rheumatoid arthritis with an inadequate response to tumour necrosis factor inhibitor therapies 2008 ·Annals of the Rheumatic Diseases ·Edward Keystone, Paul Emery, Charles Peterfy, PP Tak, Stanley Cohen, Mark C. Genovese, Maxime Dougados, Gerd R Burmester, Maria Greenwald, Tore K Kvien, S. Williams, David Hagerty, Matt Cravets, (unknown)	173

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact